Hepatitis

People with hepatitis C who show higher values of liver scarring markers before starting antiviral therapy are significantly more likely to later develop…

New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…

PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…

Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…

The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…

Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…

A Phase 1 clinical trial testing PBGENE-HBV, a gene-editing therapy for chronic hepatitis B, is now recruiting patients at Massachusetts General Hospital in…

A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…

A three-year program in Oregon is receiving a $7.5-million federal grant to improve healthcare for rural residents who use recreational drugs. The program will use…

The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…